The study’s findings were presented at the American Heart Association’s Scientific Sessions on Nov. 16. In the test, Eko’s DUO stethoscope was able to detect with significant accuracy an ejection fraction of less than 35 percent, which indicates an increased risk of life-threatening irregular heartbeats associated with sudden cardiac arrest and death.
According to a news release, the Eko DUO is the first point-of-care device combining a single-lead ECG with an AI algorithm to achieve such successful results.
Mayo Clinic and Eko first announced their collaboration to develop a less expensive and time-consuming system to detect low ejection fraction in October 2018. Additionally, Mayo Clinic recently participated in the software company’s $20 million Series B funding round.
More articles on AI:
Microsoft AI, research head steps down
Healthcare leaders debunk 3 myths about machine learning
Baystate Health to develop AI tools that match patients to clinical trials
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
